US 11,053,256 B2
Dihydropyranopyrimidines for the treatment of viral infections
Tim Hugo Maria Jonckers, Heist-op-den-Berg (BE); Pierre Jean-Marie Bernard Raboisson, Wavre (BE); Jérôme Émile Georges Guillemont, Andé (FR); David Craig McGowan, Brussels (BE); Werner Constant Johan Embrechts, Beerse (BE); Ludwig Paul Cooymans, Beerse (BE); and Laurent Calmus, Braine l'Alleud (BE)
Assigned to Janssen Sciences Ireland Unlimited Company, County Cork (IE)
Appl. No. 16/312,687
Filed by Janssen Sciences Ireland Unlimited Company, County Cork (IE)
PCT Filed Jun. 30, 2017, PCT No. PCT/EP2017/066307
§ 371(c)(1), (2) Date Dec. 21, 2018,
PCT Pub. No. WO2018/002319, PCT Pub. Date Jan. 4, 2018.
Claims priority of application No. 16177401 (EP), filed on Jul. 1, 2016.
Prior Publication US 2019/0322678 A1, Oct. 24, 2019
Int. Cl. A61K 31/517 (2006.01); C07D 491/052 (2006.01)
CPC C07D 491/052 (2013.01) 11 Claims
1. A method of treating viral hepatitis in which the activation of TLR7 and/or TLR8 is involved in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), (II) or (III) having the structure

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, tautomer, stereo-isomeric form, or solvate thereof, wherein
R1 is C1-6 alkyl substituted by one or more substituents independently selected from hydroxyl or C1-3alkoxy;
R2 is selected from hydrogen, fluorine, C1-3 alkyl, cyclopropyl, —CF3, C1-3alkoxy or nitrile.